Potential role for angiotensin-converting enzyme inhibitors in the treatment of patients with normal-tension glaucoma

我们研究坎地沙坦，一种血管紧张素II型受体阻滞剂，对青光眼动物模型视网膜神经节细胞（RGCs）的神经毒性的神经保护作用。烧灼大鼠3条外膜血管，使其单眼眼压长期升高。然后给大鼠口服坎地沙坦（1mg/kg/天）。与对侧对照眼相比，实验期间IOP持续升高约2.5倍。与眼压正常的对侧对照眼相比，慢性眼压升高的眼睛中央视网膜的RGC存活率，未治疗组为46.5%，坎地沙坦治疗组为84.2%。在大鼠慢性青光眼模型中，连续使用坎地沙坦进行药物治疗对RGC丧失具有显著的神经保护作用。

We investigate the neuroprotective effect of candesartan, an angiotensin II type 1 receptor blocker, against the neurotoxicity of the retinal ganglion cells (RGCs) in an animal model of glaucoma. Cauterization of 3 episcleral vessels in rats was used to create chronically and elevated intraocular pressure (IOP) in one eye. Rats were then orally treated with candesartan (1mg/kg/day). As compared to the contralateral control eyes, there was a consistently elevated IOP of approximately 2.5-fold during the experimental period. As compared to the contralateral control eyes that had normal IOPs, the RGC survival rate in the central retina of eyes with the chronic, elevated IOP was 46.5% in the untreated animals and 84.2% in the candesartan-treated animals. In the rat chronic glaucoma model, continuous pharmacological treatment using candesartan results in significant neuroprotection against RGC loss.